↑ 疾患リストへ ← 戻る

 331. 特発性多中心性キャッスルマン病 [臨床試験数:18,薬物数:37(DrugBank:24),標的遺伝子数:30,標的パスウェイ数:140] 

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03864419October 24, 20194 November 2019Rituximab Hyaluronidase and Combination Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaA Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics Children, Adolescents, and Adults in UgandaBurkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell LymphomaBiological: Rituximab or Rituximab Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotrexate;Drug: Doxorubicin;Drug: Doxorubicin Hydrochloride;Drug: Prednisone;Drug: EtoposideFred Hutchinson Cancer Research CenterNational Cancer Institute (NCI)Recruiting2 YearsN/AAll40Phase 1United States
2JPRN-jRCT207119002909/10/20195 November 2019Sirolimus study in refractory idiopathic multicentric Castleman's diseaseRandomized, double-blind, placebo-controlled, parallel-group trial of Sirolimus for Tocilizumab-resistant idiopathic multicentric Castleman disease.idiopathic multicentric Castleman's disease
Castleman's disease
Treatment: Sirolimus 2 mg po once/day.
Control: Placebo given orally once daily
Atsushi KawakamiNot Recruiting>= 18age oldNot applicableBoth20Phase 2none
3NCT03933904September 25, 201914 October 2019Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseA Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseCastleman Disease;Castleman's Disease, MulticentricDrug: SirolimusUniversity of PennsylvaniaRecruiting18 Years80 YearsAll24Phase 2United States
4NCT03982771January 1, 201924 June 2019BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot TrialIdiopathic Multicentric Castleman's DiseaseDrug: Bortezomib;Drug: Cyclophosphamide;Drug: DexamethasonPeking Union Medical College HospitalRecruiting18 YearsN/AAll30Phase 2China
5NCT03043105January 1, 201716 December 2017TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot TrialThalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot TrialMulticentric Castleman DiseaseDrug: Thalidomide, cyclophosphamide and prednisonePeking Union Medical College HospitalRecruiting18 YearsN/AAll55Phase 2China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02228512August 15, 201410 September 2018Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasPhase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;Primary Effusion LymphomaDrug: Cyclophosphamide;Drug: Pomalidomide;Drug: Rituximab;Drug: Prednisone;Drug: Etoposide;Drug: Doxorubicin;Drug: VincristineNational Cancer Institute (NCI)Not recruiting18 Years99 YearsAll0Phase 1/Phase 2United States
7NCT02080416July 201420 June 2016Nelfinavir for the Treatment of Gammaherpesvirus-Related TumorsA Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related TumorsNon-Hodgkin Lymphoma;Hodgkin Lymphoma;Kaposi Sarcoma;Gastric Cancer;Nasopharyngeal Cancer;EBV;Castleman DiseaseDrug: NelfinavirSidney Kimmel Comprehensive Cancer CenterNot recruiting18 YearsN/ABoth1Phase 0United States
8NCT01552434March 16, 201230 September 2019Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseA Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsAdvanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland NeoplasmBiological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic AcidM.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingN/AN/AAll216Phase 1United States
9NCT01441063September 13, 201111 November 2019Tocilizumab for KSHV-Associated Multicentric Castleman DiseasePilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman DiseaseCastleman Disease;Castleman's Disease;Giant Lymph Node HyperplasiaDrug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)National Cancer Institute (NCI)Recruiting18 YearsN/AAll17Phase 2United States
10NCT01400503April 1, 201111 June 2018A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's DiseaseAn Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's DiseaseMulticentric Castleman's DiseaseDrug: SiltuximabJanssen Research & Development, LLCNot recruiting18 YearsN/AAll60Phase 2United States;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2009-012380-34-GB18/05/201011 September 2012A study of the safety and efficacy of CNTO328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's DiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s DiseaseMulticentric Castleman's disease
MedDRA version: 14.1 Level: PT Classification code 10050251 Term: Castleman's disease System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Multicentric Castleman's disease
MedDRA version: 14.1 Level: PT Classification code 10050251 Term: Castleman's disease System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: CNTO 328
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100 and 400-
Pharmaceutical form of the placebo: Powder for solution for infusion
Route of administration of the placebo: Intravenous use
Product Code: CNTO328
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: CNTO 328
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100 and 400-
Pharmaceutical form of the placebo: Powder for solution for infusion
Route of administration of the placebo: Intravenous use
Janssen-Cilag International N.V.AuthorisedFemale: yes
Male: yes
78Hungary;Germany;Malaysia;Netherlands;France;Norway;Singapore;Hong Kong;Australia;Brazil;Israel;India;United Kingdom;Russian Federation;New Zealand;Canada;Egypt;Taiwan;Belgium;Korea, Republic of;China;Spain;United States
12NCT00891280February 200919 February 2015Dose-escalation Study of Oral CX-4945A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple MyelomaAdvanced Solid Tumors;Breast Cancer;Inflammatory Breast Cancer;Castleman's Disease;Multiple MyelomaDrug: CX-4945 oral formulationCylene PharmaceuticalsRecruiting18 YearsN/ABoth55Phase 1United States
13NCT00361933December 200816 December 2017Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's DiseaseClinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to ValganciclovirGiant Lymph Node HyperplasiaDrug: ValganciclovirUniversity of WashingtonHoffmann-La RocheNot recruiting18 YearsN/AAll0Phase 4United States
14NCT01183598August 200614 November 2016A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra TreatmentProvision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab TreatmentCastleman's DiseaseDrug: tocilizumab [RoActemra/Actemra]Hoffmann-La RocheNot recruiting18 YearsN/ABoth3Phase 1United States
15NCT00412321May 200519 February 2015A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseA Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseLymphoma, Non-Hodgkin;Multiple Myeloma;Giant Lymph Node HyperplasiaDrug: CNTO 328Centocor, Inc.Not recruiting18 YearsN/ABoth67Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00092222October 28, 200411 November 2019Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityTargeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease ActivityLymphoproliferative Disorder;HHV-8;Malignancy;HIVDrug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation OnlyNational Cancer Institute (NCI)Recruiting12 Years65 YearsAll72Phase 2United States
17NCT00127569May 200319 February 2015Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on ChemotherapyMulticenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB)HIV Infections;Giant Lymph Node HyperplasiaDrug: RituximabFrench National Agency for Research on AIDS and Viral HepatitisHoffmann-La RocheNot recruiting18 YearsN/ABoth25Phase 2
18NCT00002652May 199519 February 2015Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's DiseaseA PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASEMultiple Myeloma and Plasma Cell NeoplasmDrug: suraminUniversity of ArkansasNational Cancer Institute (NCI)Not recruiting18 YearsN/ABothPhase 2United States

先頭へ